Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises | Immunotherapy
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art | Bentham Science
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives | Journal of Neurology
Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. - Abstract - Europe PMC
Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies | Scientific Reports
AntiCD20+ Agents - Practical Neurology
Mechanisms of action of anti-CD20 monoclonal antibodies. Abbreviation:... | Download Scientific Diagram
An Overview of CD20 Monoclonal Antibodies Drugs- CUSABIO
Lymphatics | Free Full-Text | A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas
Anti-CD20 monoclonal antibodies: historical and future perspectives | Haematologica
The applications of anti-CD20 antibodies to treat various B cells disorders - ScienceDirect
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance | Oncogene
Antibody drug development: Targeting CD20 and CD3
CD20 — Wikipédia
Protéine CD20 pleine longueur exprimée HEK293 avec Nanodisc / DDM / VLP - ACROBiosystems
Comparison of commercially available anti-CD20 antibodies | Download Table
iLite® CD20 (+) Target
Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus - ScienceDirect
Anticorps monoclonal anti-CD20 (rituximab) dans les maladies hématologiques et les affections auto-immunes - ScienceDirect
anti-CD20 (Rituximab) - ACE Biolabs Antibody │ Chemical │ Enzyme
Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy | PNAS
Frontiers | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
The future of anti-CD 20 monoclonal antibodies : are we making progress ? | Semantic Scholar
Anti-CD20 Antibody Therapy for B-Cell Lymphomas | NEJM
